As of 2026-09-15, the Intrinsic Value of Summit Therapeutics Inc (SMMT) is -5.37 USD. This SMMT valuation is based on the model Peter Lynch Fair Value. With the current market price of 18.42 USD, the upside of Summit Therapeutics Inc is -129.13%.
Based on its market price of 18.42 USD and our intrinsic valuation, Summit Therapeutics Inc (SMMT) is overvalued by 129.13%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.37 - -5.37 | -5.37 | -129.13% |
| P/E | (20.60) - (25.33) | (22.11) | -220.0% |
| DDM - Stable | (7.31) - (24.28) | (15.80) | -185.8% |
| DDM - Multi | (0.06) - (0.16) | (0.09) | -100.5% |
| Market Cap (mil) | 14,694.55 |
| Beta | 2.28 |
| Outstanding shares (mil) | 797.75 |
| Enterprise Value (mil) | 14,275.19 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.12% |
| Cost of Debt | 5.00% |
| WACC | 7.40% |